Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 adaptive open-label study of intra-articular AMB-05X in tenosynovial giant cell tumor
2023-507328-22-00Phase 2Completed
- Sponsor
- AmMax Bio
- Start
- Dec 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, open-label trial of ABM-05X in tenosynovial giant cell tumor (TGCT) (2 arms), sponsored by AmMax Bio. Primary endpoints: Objective response rate at Week 24 in Part 1 by RECIST v1.1 and Treatment-emergent adverse events. Started Dec 2022; status: completed.
02
Drugs
ABM-05X
03
Conditions
tenosynovial giant cell tumor (TGCT)
Beyond the preview
Go deeper on 2023-507328-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507328-22-00.